Literature DB >> 1471208

Mechanisms of cytotoxicity caused by antitumour drugs.

J A Hickman1, H M Beere, A C Wood, C M Waters, R Parmar.   

Abstract

Although the nature of the interaction between a drug or toxin and its target is of critical importance in determining the fate of a cell, we have argued here that the biological outcome of that interaction will also be determined by the nature of cellular events "downstream" of the initial interactions. We suggest that some type of coupling must take place between the formation of a drug-target interaction (the stimulus?) and the response of the cell. That response will depend upon the phenotypically determined repertoire of response open to the cell as well as upon the quantitative and qualitative measures of the events that the drug induces (DNA or protein damage, inhibition of growth etc.). For example we have described how the HL-60 cell appears to respond to low levels of toxins by engaging a programme of terminal differentiation whilst at greater concentrations apoptosis becomes engaged. Consideration of the cellular response to a toxic insult may provide valuable insights into the selective toxicity of agents as well as providing avenues for the discovery of toxins which might be useful in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1471208     DOI: 10.1016/0378-4274(92)90231-8

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  6 in total

1.  The cell cycle and induction of apoptosis in a hamster fibrosarcoma cell line treated with anti-cancer drugs: its importance to solid tumour chemotherapy.

Authors:  S el Alaoui; J Lawry; M Griffin
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.

Authors:  Ahmet Bilici; Bala Basak Oven Ustaalioglu; Serif Ercan; Mesut Seker; Burcak Erkol Yilmaz; Asuman Orcun; Mahmut Gumus
Journal:  Tumour Biol       Date:  2012-08-14

3.  The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer.

Authors:  Bala Basak Oven Ustaalioglu; Ahmet Bilici; Serif Ercan; Mesut Seker; Asuman Orcun; Mahmut Gumus
Journal:  Med Oncol       Date:  2013-03-28       Impact factor: 3.064

4.  Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients.

Authors:  Engin Ulukaya; Esra Karaagac; Ferda Ari; Arzu Y Oral; Saduman B Adim; Asuman H Tokullugil; Türkkan Evrensel
Journal:  Radiol Oncol       Date:  2011-03-15       Impact factor: 2.991

5.  The roles of M30 and M65 in the assessment of treatment response and prognosis in patients with non-small cell lung cancer, who receive neoadjuvant treatment.

Authors:  Belkıs Nihan Coskun; Oguzhan Sıtkı Dizdar; Seniz Korkmaz; Engin Ulukaya; Turkkan Evrensel
Journal:  Contemp Oncol (Pozn)       Date:  2019-12-30

6.  Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages.

Authors:  Florian Janke; Farastuk Bozorgmehr; Sabine Wrenger; Steffen Dietz; Claus P Heussel; Gudula Heussel; Carlos F Silva; Stephan Rheinheimer; Manuel Feisst; Michael Thomas; Heiko Golpon; Andreas Günther; Holger Sültmann; Thomas Muley; Sabina Janciauskiene; Michael Meister; Marc A Schneider
Journal:  Cancers (Basel)       Date:  2020-04-12       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.